


Pharmaceuticals & Biotechnology | Small Cap
Hikal Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, indicating a solid foundation and effective management in these areas. However, liquidity and efficiency are areas of concern, suggesting potential challenges in meeting short-term obligations and optimizing asset utilization. The company's coverage ratios are reasonably good, reflecting its ability to meet its interest and dividend commitments. While the financial ratios are weak, the other strong areas provide a somewhat balanced view. Overall, Hikal Ltd appears to be a company with considerable strengths in long-term sustainability and earnings potential, but it needs to address its short-term financial management to ensure continued success.
Hikal Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, indicating a solid foundation and effective management in these areas. However, liquidity and efficiency are areas of concern, suggesting potential challenges in meeting short-term obligations and optimizing asset utilization. The company's coverage ratios are reasonably good, reflecting its ability to meet its interest and dividend commitments. While the financial ratios are weak, the other strong areas provide a somewhat balanced view. Overall, Hikal Ltd appears to be a company with considerable strengths in long-term sustainability and earnings potential, but it needs to address its short-term financial management to ensure continued success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-56.06
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
-55.92
P/B RATIO
2.28
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
1.55
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
20.27
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹221.43 as on Aug 6, 2026.
The company exhibits strong growth across all key metrics, including revenue, operating profit, EPS, assets, and net income. The company is expanding its operations and increasing its profitability. This suggests that the company is well-positioned for future success and has a competitive advantage in the market.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 12.97 | 4.12 | -11.76 | 4.2 | -7.9 |
| Operating Profit Growth Rate | 5.57 | -24.34 | 3.49 | 22.85 | -32.93 |
| Earnings Per Share (EPS) Growth | 20.56 | -51.15 | -11.32 | 30.5 | -153.8 |
| Asset Growth Rate | 15.68 | 7.77 | 4.28 | 1.69 | |
| Net Income Growth Rate | 20.3 | -51.25 | -10.26 | 30 | -153.85 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 6 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 12 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 13 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 14 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 15 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 16 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 17 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
| 19 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral